Table 4.
Analysis of primary and secondary outcomes
| Outcome | MCID (±) | Difference between groups 7 weeks (NET-Placebo) | Difference between groups 6 months (NET-Placebo) | Time x group interaction | ||
|---|---|---|---|---|---|---|
| Mean difference (95 % CI) | P-value | Mean difference (95 % CI) | P-value | P-value | ||
| Depression | 4 | −0.58 (−4.62, 3.45) | 0.78 | −0.04 (−4.04, 3.96) | 0.98 | 0.60 |
| Anxiety | 5 | 0.63 (−2.19, 3.46) | 0.66 | 0.36 (−2.44, 3.16) | 0.80 | 0.98 |
| Stress | 4 | 0.29 (−3.63, 4.21) | 0.88 | 1.47 (−2.42, 5.35) | 0.46 | 0.86 |
| TSH | 0.75 | 0.11 (−2.64, 2.88) | 0.93 | 1.01 (−1.76, 3.77) | 0.47 | 0.49 |
| FT4 | 6.0 | 0.67 (−0.81, 2.15) | 0.37 | 0.33 (−1.14, 1.80) | 0.66 | 0.85 |
| FT3 | 1.5 | 0.29 (−0.24, 0.83) | 0.28 | 0.15 (−0.38, 0.68) | 0.58 | 0.82 |
| Physical functioning | 3.5 | −0.76 (−9.07, 7.56) | 0.86 | 1.75 (−6.41, 9.91) | 0.67 | 0.35 |
| Role physical | 3.2 | 4.25 (−7.31, 15.81) | 0.47 | 4.35 (−6.93, 15.63) | 0.45 | 0.99 |
| Bodily pain | 4.5 | 3.56 (−7.62, 14.73) | 0.53 | 2.35 (−8.43, 13.13) | 0.67 | 0.76 |
| General health | 5.7 | 2.11 (−8.20, 12.43) | 0.69 | 3.35 (−6.78, 13.47) | 0.52 | 0.28 |
| Vitality | 5.5 | 0.27 (−9.76, 10.30) | 0.96 | −0.10 (−9.84, 9.65) | 0.98 | 0.76 |
| Social functioning | 5.0 | 9.05 (−4.55, 22.66) | 0.19 | 5.58 (−7.54, 18.69) | 0.40 | 0.65 |
| Role emotional | 3.8 | 2.12 (−8.72, 12.96) | 0.70 | 1.13 (−9.36, 11.61) | 0.83 | 0.86 |
| Mental health | 5.5 | 4.73 (−5.23, 14.72) | 0.35 | 4.83 (−4.84, 14.49) | 0.33 | 0.65 |
| Mental component summary | 3.1 | 4.11 (−1.58, 9.79) | 0.16 | 0.22 (−5.25, 5.69) | 0.94 | 0.36 |
| Physical component summary | 3.8 | 1.02 (−3.14, 5.18) | 0.63 | 0.97 (−3.10, 5.03) | 0.64 | 0.50 |
MCID minimal clinically important difference, TSH thyroid stimulating hormone (mIU/L), FT4 free thyroxine (pmol/L), FT3 Free triiodothyronine (pmol/L)